VANCOUVER, BC – December 1, 2020 – Izotropic Corporation ("Izotropic" or the "Company") (CSE: IZO) (OTC US: IZOZF) (FSE: 1R3) announces that it has cancelled 600,000 options previously issued to consultants.
The Company also announces that further to its News Release of October 30, 2020, whereby it announced the closing of a second and final tranche of its non-brokered private placement (the "Offering") of 2,866,334 units (each, a "Unit") at a price of $0.55 per Unit for gross proceeds of $1,576,483.70, it wishes to disclose the updated amount of broker warrants paid in connection with the Offering to 193,995 Broker Warrants.
Robert Thast
Investor Relations: 1-778-962-0234
Izotropic Corporation and its wholly owned U.S. operating subsidiary, Izotropic Imaging Corp. have been established to commercialize the next generation of breast imaging technology for early diagnosis of breast cancer. The Izotropic Breast CT Imaging System produces high resolution breast images in 3D. A single 10 second breast CT scan acquires approximately 500 images, without painful breast compression, providing radiologists with fully 3D viewing of the scanned breast.
Mammography scanning requires compression of the breast between 2 imaging plates, resulting in 2D images.
The Company has the exclusive worldwide license from the University of California, Davis (UC Davis) to commercialize the technology developed by principal founder and Company director Dr. John M. Boone and researchers at UC Davis. The license includes all intellectual property, trade secrets, patents and patent-pending applications that are the foundation of the Company's breast CT imaging platform.
Approximately $20 million in research funding and over 15 years of research and development have been invested in developing this groundbreaking breast CT imaging technology. Research includes a current, ongoing $2.9M U.S. clinical trial at UC Davis Medical Center.